Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

443
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

313
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
278

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Features of Importance in the Nasal Exam in Rhinoplasty.

Facial plastic surgery & aesthetic medicine·2026
Same author

Carving Out Change: Women Leading in Facial Plastic Surgery.

Facial plastic surgery & aesthetic medicine·2026
Same author

Use of Augmented Reality Technology in Cosmetic Rhinoplasty: A Feasibility Study.

Facial plastic surgery & aesthetic medicine·2026
Same author

Postoperative Pain Management in Rhinoplasty: A Double Blind Randomized Controlled Trial.

Facial plastic surgery & aesthetic medicine·2026
Same author

What to Expect With Skin Cancer Reconstruction.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Risk Factors of Persistent Opioid Use After Forehead Flap Reconstruction.

The Annals of otology, rhinology, and laryngology·2026
Same journal

Gender-Affirming Care in Otolaryngology: A State of the Art Review.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

Caffeine Consumption and Rhinologic Symptom Severity.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

Ethical Considerations in Using the Pernkopf Atlas in Otolaryngology Education Ethics in Practice: Point-Counterpoint.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Recurrence in HPV-Associated Oropharyngeal Cancer After Transoral Robotic Surgery.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

PEAK-II Trach: A Multi-Institutional Quality Improvement/Simulation Study Assessing Pediatric Emergency Readiness.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
Same journal

Clinical Features, Treatment, and Outcomes for Oropharyngeal Adenoid Cystic Carcinoma: A Systematic Review.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm
06:53

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm

Published on: July 23, 2020

5.7K

Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.

Rahul K Sharma1, Kelly L Vittetoe1, Alexander J Barna1

  • 1Vanderbilt University Medical Center, Division of Facial Plastic and Reconstructive Surgery, Nashville, Tennessee, USA.

Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery
|May 23, 2025
PubMed
Summary
This summary is machine-generated.

Weight-loss drugs like semaglutide can cause facial deflation, commonly known as "Ozempic face." Patients lose an average of 7% midfacial volume for every 10kg lost, primarily from superficial fat pads.

Keywords:
GLP‐1 agonistsOzempicfacial volumemedical weight lossmidfacial volumesemaglutide

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.0K
Quantification of Orofacial Phenotypes in Xenopus
09:26

Quantification of Orofacial Phenotypes in Xenopus

Published on: November 6, 2014

9.9K

Related Experiment Videos

Last Updated: Sep 20, 2025

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm
06:53

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm

Published on: July 23, 2020

5.7K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.0K
Quantification of Orofacial Phenotypes in Xenopus
09:26

Quantification of Orofacial Phenotypes in Xenopus

Published on: November 6, 2014

9.9K

Area of Science:

  • Plastic Surgery
  • Medical Imaging
  • Pharmacology

Background:

  • Facial plastic surgeons observe increased patientS with facial deflation and premature aging, potentially linked to semaglutide use.
  • No objective data currently quantifies midface volume loss associated with this weight-loss medication.

Purpose of the Study:

  • To quantitatively assess midface volume changes in patients using glucagon-like peptide-1 (GLP-1) agonists.
  • To investigate the correlation between the magnitude of weight loss and facial volume reduction.

Main Methods:

  • Retrospective cohort study at a single tertiary academic medical center.
  • Analysis of electronic medical records and head/neck imaging (CT/MR) from 2017-2024 for patients on GLP-1 agonists.
  • Measurement of changes in total, superficial, and deep midface volume, with statistical analysis of weight loss correlation.

Main Results:

  • Twenty patients were included, with an average weight loss of 11.0 kg over 321 days.
  • Median total midfacial volume decreased by 9.0%, with superficial volume decreasing by 11.0% and deep volume by 7.0%.
  • A significant correlation was found between weight loss and superficial volume loss (rho=0.590, P=0.006). Linear regression indicated a 7% midfacial volume loss per 10 kg weight loss.

Conclusions:

  • Patients can expect approximately 7% midfacial volume loss per 10 kg of weight lost, predominantly affecting superficial fat.
  • This study provides early quantitative evidence for the "Ozempic face" phenomenon, highlighting changes in facial volume due to GLP-1 agonist therapy.